Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Forecast
KNSA analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.88 / 5 from 8 analysts
- Price target
- $98.00 average of analyst targets
- Upside to target
- +24.7% from the latest close
- Next earnings
- October 27, 2026 EPS estimate $0.39
- 52-week range
- $37.01 – $80.92
KNSA analyst ratings
8 analystsNumber of analysts at each rating.
KNSA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KNSA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.32 | $0.28 | $0.37 | $0.23 | +37.0% | 4 |
| Current fiscal year (2026) | $1.16 | $1.07 | $1.23 | $0.75 | +54.3% | 4 |
| Next fiscal year (2027) | $1.62 | $1.28 | $1.93 | $1.16 | +39.7% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KNSA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $260.2M | $258.0M | $265.0M | +43.9% | 8 |
| Current fiscal year (2026) | $994.4M | $989.7M | $1.00B | +46.8% | 8 |
| Next fiscal year (2027) | $1.22B | $1.12B | $1.35B | +22.9% | 8 |
KNSA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KNSA revenue: reported and forecast
KNSA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.31 | $0.32 | $0.32 | $0.32 | $0.32 | +2.4% | 2 up · 2 down |
| Current fiscal year (2026) | $1.16 | $1.16 | $1.16 | $1.16 | $1.16 | −0.2% | 1 up · 2 down |
| Next fiscal year (2027) | $1.70 | $1.62 | $1.62 | $1.62 | $1.62 | −5.0% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KNSA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KNSA beat in 3 of 12.
What analysts expect from KNSA
8 analysts cover Kiniksa Pharmaceuticals; their consensus rating is strong buy (4.88 on a 1–5 scale, where 5 is a strong buy). The average price target is $98.00, 24.7% above the latest close of $78.59. Analysts expect earnings of $1.16 per share for 2026, +54.3% from a year earlier. For 2027 the average estimate is $1.62 per share on revenue of $1.2 billion. Kiniksa Pharmaceuticals beat the EPS estimate in 3 of the last 12 quarters.
Related: KNSA income statement, KNSA key metrics, KNSA chart. See the KNSA stock overview for the latest quote and news.
KNSA forecast FAQ
What is Kiniksa Pharmaceuticals's price target?
The average analyst price target for Kiniksa Pharmaceuticals is $98.00, 24.7% above the latest close of $78.59.
Is Kiniksa Pharmaceuticals a buy, hold or sell?
Of 8 analysts covering Kiniksa Pharmaceuticals, 7 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Kiniksa Pharmaceuticals's EPS forecast?
Analysts forecast $1.16 per share for 2026 (range $1.07 to $1.23); for 2027 the estimate is $1.62.
What is Kiniksa Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $994.4 million, growth of 46.8%; for 2027 it is $1.2 billion.
When does Kiniksa Pharmaceuticals report earnings?
Kiniksa Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 before the market opens; the EPS estimate is $0.39.
Does Kiniksa Pharmaceuticals usually beat earnings estimates?
Kiniksa Pharmaceuticals reported EPS at or above the analyst estimate in 3 of the last 12 quarters.